



(43) International Publication Date  
25 July 2013 (25.07.2013)

(10) International Publication Number  
**WO 2013/109876 A1**

(51) International Patent Classification:

*A61K 38/16* (2006.01) *A61K 31/145* (2006.01)  
*A61K 45/06* (2006.01) *A61P 3/10* (2006.01)  
*A61K 48/00* (2006.01)

(21) International Application Number:

PCT/US2013/022126

(22) International Filing Date:

18 January 2013 (18.01.2013)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/588,959 20 January 2012 (20.01.2012) US

(71) Applicant: BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE [US/US]; 6400 Perkins Road, B1035, Pennington Biomedical Research Center, Baton Rouge, Louisiana 70808-4124 (US).

(72) Inventors; and

(71) Applicants : DHURANDHAR, Nikhil [US/US]; 11152 South Lakeside Oaks Ave., Baton Rouge, Louisiana 70810 (US). KRISHNAPURAM, Rashmi [IN/US]; 4155 Essen Lane, Apt. No. 180, Baton Rouge, Louisiana 70809 (US).

(74) Agents: UNDERWOOD, Robert H. et al.; McDermott Will & Emery LLP, 28 State Street, Boston, Massachusetts 02109 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,

BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: ENHANCED GLYCEMIC CONTROL USING AD36E4ORF1 AND AKT1 INHIBITOR

(57) Abstract: This invention generally relates to methods for improving glyceemic control by administering an Ad36 composition and an AKT1 inhibitor.



WO 2013/109876 A1

## ENHANCED GLYCEMIC CONTROL USING Ad36E4orf1 AND AKT1 INHIBITOR

### RELATED APPLICATIONS

[001] This application claims the benefit of U.S. Provisional Application No. 61/588,959, filed on January 20, 2012, the entire teachings of these applications are incorporated herein by reference.

### BACKGROUND

[002] The binding of insulin to its cell surface receptor initiates a cascade of cell signaling, which involves the activation of phosphatidyl inositol 3-kinase (PI3K) via the insulin receptor substrates (IRS) (Figure 1). PI3K in turn activates the enzyme AKT, leading to the translocation of glucose transporters (Glut4) to cell surface. Glucose transporters bring glucose inside a cell. A defect in cellular uptake of glucose can lead to accumulation of glucose outside a cell (in circulation), leading to a hyperglycemic or diabetic state. In contrast, increasing cellular glucose uptake can clear it from the circulation, thus improving hyperglycemia or diabetes.

[003] Ad36 is a human adenovirus that increases adiposity in experimentally infected animals, yet improves their glycemic control (1, 2). In humans, natural infection with Ad36 is associated with better glycemic control (1). Cell signaling studies have shown that Ad36 up-regulates PI3K activation, not via the conventional insulin-IRS pathway, but instead via activating Ras (Figure 1), which leads to enhanced uptake of glucose in adipocytes and myocytes (3-5). In adipocytes and their progenitors, Ad36 up-regulates PPAR $\gamma$ , a key gene that initiates adipogenesis, which leads to a greater differentiation of fat cells, and lipid accumulation, and consequentially, greater adiposity (6, 7). On the other hand, Ad36 increases glucose

uptake in adipose tissue and adipocytes (8). Thus, Ad36 possesses the dual property of increasing adiposity, yet improving glycemic control.

[004] The adipogenic and glycemic effects of Ad36 are mediated via its E4orf1 protein, which up-regulates PPAR $\gamma$ , increases adiposity and increases cellular glucose uptake (9, 10). Up-regulation of PPAR $\gamma$  is also associated with improved glycemic control. The thiazolidinedione (TZD) class of anti-diabetic drugs up-regulate PPAR $\gamma$  and improve glycemic control, while also increasing adiposity (11, 12). The dual action of Ad36 or its E4orf1 protein is similar to that of the thiazolidinedione (TZD) drugs. Unfortunately, excess adiposity is associated with poor health and glycemic control.

[005] Many AKT inhibitors are known in the art and have been suggested for cancer therapy. (Lindsley, C.W., Curr. Topics in Med. Chem., 10(4):458-477 (2010).)

[006] Thus a need exists for new therapies that are able to improve glycemic control independent of adipogenesis.

## SUMMARY OF THE INVENTION

[007] The invention relates to methods of improving glycemic control in an individual, comprising administering to an individual in need thereof a therapeutically effective amount of an Ad36 composition and an AKT1 inhibitor, wherein glycemic control is improved without substantial increase in adipogenesis.

[008] The invention also relates to methods of treating or preventing diabetes in an individual, comprising administering to an individual in need thereof a therapeutically effective amount of an Ad36 composition and an AKT1 inhibitor, wherein the individual's symptoms improve without substantial increase in adipogenesis.

[009] The Ad36 composition can comprise an Adenovirus-36 E4orf1 protein or functional variant thereof, a nucleic acid encoding Adenovirus-36 E4orf1 or functional variant thereof, or an analog or derivative of Adenovirus-36 E4orf1. For example, the amino acid sequence of the Adenovirus-36 E4orf1 protein can be SEQ ID NO:2 or functional variant thereof. In another example, the Ad36 composition can comprise a nucleic acid sequence comprising SEQ ID NO:1 or functional variant thereof.

[010] In one aspect, a nucleic acid encoding Adenovirus-36 E4orf1 protein is administered to the individual by introducing into the individual a nucleic acid sequence encoding the Adenovirus-36 E4orf1 protein, in a manner permitting expression of the Adenovirus-36 E4orf1 protein. For example, the nucleic acid sequence is introduced by a method selected from the group consisting of electroporation, DEAE Dextran transfection, calcium phosphate transfection, cationic liposome fusion, protoplast fusion, creation of an in vivo electric field, DNA-coated microprojectile bombardment, injection with recombinant replication-defective viruses, homologous recombination, in vivo gene therapy, ex vivo gene therapy, viral vectors, and naked DNA transfer.

[011] In one aspect, the individual can be a mammal, such as a human.

[012] In one aspect, the AKT1 inhibitor can be 2-Aminothiadiaazole (2-ATD).

#### **BRIEF DESCRIPTION OF THE DRAWINGS**

[013] FIG. 1 is a schematic showing the cascade of cell signaling, which involves the activation of phosphatidyl inositol 3-kinase (PI3K) that is initiated upon binding of insulin to its cell surface receptor.

[014] FIG. 2 (A) is a Western blot showing the levels of total and phosphorylated (activated) AKT2 protein isolated from adipose tissue of HF-fed mice

killed 20 weeks after infection with adenoviruses Ad36 or Ad2 (a negative control virus); (B) is a graph showing Ad36 infected mice, but not Ad2 infected mice, had greater AKT2 activation (as indicated by greater phosphorylation) compared with mock (\* $p < 0.05$ ).

[015] FIG. 3 (A) is a Western blot showing the levels of total and phosphorylated AKT1 and AKT2 proteins isolated from adipose tissue of chow-fed mice killed 12 weeks after infection with Ad36 or Ad2 or mock infection; (B and C) are graphs showing Ad36 infected mice, but not Ad2 infected mice, had greater AKT1 and AKT2 activation, respectively, (as indicated by greater phosphorylation) compared with mock (\* $p < 0.05$  or better).

[016] FIG. 4 (A) is a Western blot showing the levels of total and phosphorylated AKT1 and AKT2 proteins from 3T3L1 cells that were induced to differentiate in to adipocytes; (B and C) are graphs showing Ad36 significantly induced increased in AKT1 and AKT2 activation, respectively, compared with mock (\* $p < 0.05$  or better). The effect of Ad36 on AKT was similar to or better than that of insulin.

[017] FIG. 5 (A) is a Western blot showing the levels of total and phosphorylated AKT2 proteins isolated from differentiated 3T3L1 adipocytes; (B) is a graph showing Ad36 significantly increased AKT2 activation compared with mock (\* $p < 0.05$ ).

[018] FIG. 6 is a graph showing glucose uptake after AKT knock down with siRNA. The data shows that AKT2, but not AKT1, is required for Ad36 to enhance cellular glucose uptake.

[019] FIG. 7A-F are photomicrographs of 3T3-L1 cells. FIGS. 7A-C show 3T3-L1 cells that carry an empty vector (pTRE) and do not express E4orf1 in response to doxycycline. FIGS. 7D-F show 3T3-L1 cells that express Ad36 E4orf1

when exposed to doxycycline, treated with 0, 1, or 5  $\mu$ M, respectively, of 2-ATD—a specific inhibitor of AKT1 signalling. The results show that 2-ATD blocked adipogenesis and lipid accumulation (staining indicates lipid accumulation).

[020] FIG. 8 (A) is a graph showing the effect of chemical inhibition of AKT1 using 2-ATD on PPAR $\gamma$  expression in an inducible E4orf1 stable cell line; (B) is a graph showing the effect of chemical inhibition of AKT1 using 2-ATD on adiponectin expression. FIGS. A and B show a down regulation of mRNA expression of adipogenic genes, PPAR $\gamma$  and adiponectin, when exposed to 2-ATD.

[021] FIG. 9 is a graph showing basal and insulin stimulated glucose uptake in the presence of 2-ATD. The graph shows that E4orf1 expression continued to increase glucose uptake, when exposed to 2-ATD.

[022] FIG. 10 is a graph showing ATD inhibits PPAR $\gamma$  protein abundance. 3T3 –L1 adipocytes were transfected with a null vector (V5), and exposed to 10  $\mu$ M TZD, or transfected with a plasmid expressing E4orf1 protein. Both groups were exposed to 0, 1 or 5  $\mu$ M ATD.

## DETAILED DESCRIPTION

### OVERVIEW

[023] Natural Ad36 infection in humans is associated with better glycemic control, but Ad36 infection also increases adiposity. As described herein, the results of studies using AKT1 inhibitors demonstrate that the Ad36 E4orf1 protein or its analogs or derivatives, in combination with an AKT1 inhibitor enhance glycemic control without inducing adipogenesis.

[024] The inventors have further discovered that an AKT1 inhibitor can block adipogenesis and lipid accumulation in preadipocytes, and reduces the

levels of mRNA encoding the adipogenic proteins PPAR $\gamma$  and adiponectin. When AKT1 is inhibited, adipogenesis is blocked, but E4orf1 continues to increase glucose uptake. The Ad36 E4orf1 structure and certain metabolic functions are described in international patent application no. PCT/US2006/045919, published as international patent publication no. WO 2007/064836 on June 7, 2007.

[025] The invention relates to methods for improving glycemic control comprising administering effective amounts of Ad36 E4orf1 or functional variants, analogs or derivatives thereof and an AKT1 inhibitor to an individual in need thereof. Based on the inventors discoveries, hyperglycemia, insulin resistance, prediabetes, diabetes type 1, and diabetes type 2 can be treated or even prevented by administering effective amounts of Ad36 E4orf1 or functional variants, analogs or derivatives thereof and an AKT1 inhibitor to an individual in need thereof.

[026] As used herein, “glycemic control” refers to the ability of the body to keep glucose levels within the normal range. Glycemic control is improved when insulin sensitivity increases. Insulin resistance has the opposite effect on glycemic control.

[027] As used herein, “glucose uptake” refers to the amount of glucose a cell will take in from its surroundings. Generally a higher glucose uptake by muscle cells or fat cells (adipocytes and preadipocytes), is beneficial, as it clears the glucose from circulation and improves hyperglycemia (higher than normal glucose in the blood).

[028] As used herein, an “analog” refers to a small molecule (e.g., less than 1 kDa) that is similar in structure to Ad-36 E4orf1 protein or fragment thereof and that exhibits a qualitatively similar effect on insulin sensitivity as does the Ad-36 E4orf1 protein.

[029] As used herein, a “derivative” refers to a modified Ad-36 E4orf1 protein or functional variant. For example a derivative may be an Ad-36 E4orf1 protein or functional variant that contains one or more D-amino acids or

non-naturally occurring amino acids, a pegylated Ad-36 E4orf1, or some other variation on the protein or function variant thereof that exhibits a qualitatively similar effect on insulin sensitivity as does the Ad-36 E4orf1 protein.

[030] As used herein, a “selective AKT1 inhibitor” is an AKT1 inhibitor, that does not substantially inhibit AKT2. For example, a selective AKT inhibitor can have an IC<sub>50</sub> for AKT1 that is lower than its IC<sub>50</sub> for AKT2 by at least a factor of 10, at least a factor of 25, or at least a factor of 50 (e.g., IC<sub>50</sub> for AKT1 inhibitor 4.6 and that for AKT2 >250 (see reference - (8)). Preferably, the selective AKT1 inhibitor does not inhibit AKT2 at all.

#### Therapeutic Methods

[031] The invention provides therapeutic methods for improving glycemic control without increasing adipogenesis. Thus, the invention provides methods for treating or preventing hyperglycemia, insulin resistance, prediabetes or diabetes (type 1 or 2) without increasing adipogenesis.

[032] In one aspect, the invention provides methods for improving glycemic control in an individual (e.g., a mammal, such as a human or other primate). Therapeutically effective amounts of an Ad36 composition and an AKT1 inhibitor are administered to an individual in need thereof to improve glycemic control in the individual.

[033] In one aspect, the invention provides methods for the treatment and prophylaxis of symptoms of hyperglycemia, insulin resistance, prediabetes or diabetes (type 1 or 2). Therapeutically effective amounts of an Ad36 composition and an AKT1 inhibitor are administered to an individual (e.g., a mammal, such as a human or other primate) in need thereof to treat or prevent hyperglycemia, insulin resistance, prediabetes or diabetes (type 1 or 2).

[034] In one aspect, the invention provides methods for treating or preventing insulin resistance. Therapeutically effective amounts of an Ad36 composition and an AKT1 inhibitor are administered is administered to an



individual (e.g., a mammal, such as a human or other primate) in need thereof to treat or prevent insulin resistance.

[035] The Ad36 composition that is administered can be an isolated or recombinant Ad36 E4orf1 protein or functional variant thereof. The Ad36 composition can also be an analog or derivative of Ad36 E4orf1 protein. The Ad36 composition that is administered can be an isolated or recombinant nucleic acid that encodes Ad36 E4orf1 protein or functional variant thereof.

[036] The AKT1 inhibitor can be administered before, substantially concurrently with, or subsequent to administration of the Ad36 composition. Preferably, the Ad36 composition and the AKT1 inhibitor are administered so as to provide substantial overlap in their pharmacological activities and provide improved glycemic control without substantially increasing adipogenesis (e.g., no more than 5%, preferably no more than 10% increase in adipogenesis). For example, the AKT1 inhibitor and Ad36 composition can be co-formulated and administered concurrently.

#### Ad36 Compositions

[037] The Ad36 composition administered in accordance with the invention can have a variety of forms. Preferably, the composition comprises E4orf1 or a functional variant thereof. For example, the Ad36 composition can be the Ad36 virus or an attenuated variant, or an inactivated form of Ad36, such as a heat-killed or bleach-killed Ad36 or a replication deficient recombinant Ad36. The Ad36 composition can comprise an isolated or recombinant Ad36 protein, preferably the E4orf1 protein or a functional variant thereof. The Ad36 composition can comprise a nucleic acid encoding the E4orf1 protein or a functional variant thereof. The Ad36 composition can comprise an analog or derivative of E4orf1 protein, for example a chemical analog or structural analog.

#### Proteins and Peptides

**[038]** The Ad36 composition can comprise an isolated or recombinant Ad36 protein, preferably the E4orf1 protein or a functional variant thereof. Proteins or polypeptides referred to herein as "isolated" are proteins or polypeptides purified to a state beyond that in which they exist in infected mammalian cells. Ad36 proteins, including E4orf1 and functional variants thereof, can be produced using well-known methods, such as recombinant expression and purification, chemical synthesis (e.g., synthetic peptides), or by combinations of biological and chemical methods, and recombinant proteins or polypeptides which are isolated. The proteins can be obtained in an isolated state of at least about 50% by weight, preferably at least about 75% by weight, and more preferably, in essentially pure form. Proteins or polypeptides referred to herein as "recombinant" are proteins or polypeptides produced by the expression of recombinant nucleic acids.

**[039]** As used herein "Ad36 E4orf1" refers to naturally occurring or endogenous E4orf1 proteins from Adenovirus 36, to proteins having an amino acid sequence which is the same as that of a naturally occurring or endogenous corresponding Ad36 E4orf1 (e.g., recombinant and synthetic proteins), and to functional variants of each of the foregoing (e.g., functional fragments and/or mutants produced via mutagenesis and/or recombinant techniques). Accordingly, as defined herein, the term includes mature Ad36 E4orf1, glycosylated or unglycosylated Ad36 E4orf1 proteins, polymorphic or allelic variants, and other isoforms of Ad36 E4orf1 (e.g., produced by alternative splicing or other cellular processes), and functional fragments.

**[040]** "Functional variants" of Ad36 E4orf1 include functional fragments, and functional mutant proteins. Generally, fragments or portions of Ad36 E4orf1 encompassed by the present invention include those having a deletion (i.e., one or more deletions). For example, 1 to about 75, e.g., 1 to about 50, or 1 to about 25, or 1 to about 10 contiguous or non-contiguous amino acids can be deleted from Ad36 E4orf1. The integrity of the PDZ domain binding motif

(the last four amino acids of SEQ ID NO:2) should be maintained, as it is a critical region that should not be altered. Fragments or portions in which only contiguous amino acids have been deleted or in which non-contiguous amino acids have been deleted relative to mature Ad36 E4orf1 are also envisioned. Generally, mutants or derivatives of Ad36 E4orf1, encompassed by the present invention include natural or artificial variants differing by the addition, deletion and/or substitution of one or more contiguous or non-contiguous amino acid residues, or modified polypeptides in which one or more residues is modified, and mutants comprising one or more modified residues. Preferred mutants are natural or artificial variants of Ad36 E4orf1 differing by the addition, deletion and/or substitution of one or more contiguous or non-contiguous amino acid residues.

[041] A "functional fragment or portion" of Ad36 E4orf1 refers to an isolated and/or recombinant protein or oligopeptide which has at least one property, activity and/or function characteristic of Ad36 E4orf1, such as attenuating hepatic steatosis, enhancing glucose disposal, and/or improving glycemic control.

[042] The Ad36 composition can also contain functional fusion proteins that comprise E4orf1 or a functional fragment or variant thereof and a heterologous amino acid sequence.

[043] Generally, the Ad36 E4orf1 or functional variant has an amino acid sequence which is at least about 85% similar, at least about 90% similar, at least about 95% similar, at least about 96% similar, at least about 97% similar, at least about 98% similar, or at least about 99% similar to SEQ ID NO:2 or SEQ ID NO:4 over the length of the variant.

[044] In some embodiments, SEQ ID NO:1 or SEQ ID NO:3 are used to make purified protein of Ad-36 E4orf1, for example, using currently available recombinant protein production. Amino acid sequence identity can be determined using a suitable amino acid sequence alignment algorithm, such as CLUSTAL W,

using the default parameters. (Thompson J. D. et al., Nucleic Acids Res. 22:4673-4680 (1994).)

#### Nucleic Acids and Vectors

[045] The Ad36 composition can comprise an isolated or recombinant nucleic acid or vector encoding a protein of Ad36, preferably the E4orf1 protein or a functional variant thereof.

[046] An isolated and/or recombinant (including, e.g., essentially pure) nucleic acids which encode an Ad36 E4orf1 protein or functional variant thereof can be administered to cause Ad36 E4orf1 production *in situ*. Nucleic acids referred to herein as "isolated" are nucleic acids separated away from the nucleic acids of the genomic DNA or cellular RNA of their source of origin (e.g., as it exists in cells or in a mixture of nucleic acids such as a library), and may have undergone further processing. "Isolated" nucleic acids include nucleic acids obtained by methods described herein, similar methods or other suitable methods, including essentially pure nucleic acids, nucleic acids produced by chemical synthesis, by combinations of biological and chemical methods, and recombinant nucleic acids which are isolated. Nucleic acids referred to herein as "recombinant" are nucleic acids which have been produced by recombinant DNA methodology, including those nucleic acids that are generated by procedures which rely upon a method of artificial recombination, such as the polymerase chain reaction (PCR) and/or cloning into a vector using restriction enzymes. "Recombinant" nucleic acids are also those that result from recombination events that occur through the natural mechanisms of cells, but are selected for after the introduction to the cells of nucleic acids designed to allow and make probable a desired recombination event.

[047] Isolated and/or recombinant nucleic acids meeting these criteria comprise nucleic acids having sequences identical to sequences encoding naturally occurring Ad36 E4orf1 and portions thereof, or functional variants of the

naturally occurring sequences. Such functional variants include mutants differing by the addition, deletion or substitution of one or more residues as described further herein, and may be encoded by modified nucleic acids in which one or more nucleotides is modified (e.g., DNA or RNA analogs), for example. The sequence can be codon-optimized or codon de-optimized for expression in the individual.

**[048]** In one aspect, the Ad36 E4orf1 or functional variant is encoded by a nucleic acid that has a nucleic acid sequence which is at least about 85% similar, at least about 90% similar, at least about 95% similar, at least about 96% similar, at least about 97% similar, at least about 98% similar, or at least about 99% similar to SEQ ID NO:1 or SEQ ID NO:3 over the length of the variant. Nucleic acid sequence identity can be determined using a suitable nucleic acid sequence alignment algorithm, such as CLUSTAL W, using the default parameters. (Thompson J. D. et al., *Nucleic Acids Res.* 22:4673-4680 (1994).)

**[049]** The nucleic acid can be in the form of DNA, RNA, and can be either single or double stranded. Generally, the nucleic acid is operably linked to expression control sequences such as an origin of replication, a promoter, and an enhancer (see, e.g., Queen, et al., *Immunol. Rev.* 89:49-68, 1986). A number of suitable vectors for expression of recombinant proteins in desired cells are well-known and conventional in the art. Suitable vectors can contain a number of components, including, but not limited to one or more of the following: an origin of replication; a selectable marker gene; one or more expression control elements, such as a transcriptional control element (e.g., a promoter, an enhancer, a terminator), and/or one or more translation signals; and a signal sequence or leader sequence for targeting to the secretory pathway in a selected host cell. If desired, the vector can include a detectable marker.

**[050]** In certain embodiments, the expression vectors are used in gene therapy. Expression requires that appropriate regulatory elements be provided in the vectors, such as enhancers/promoters from that drive expression of the genes

of interest in host cells. Elements designed to optimize messenger RNA stability and translatability in host cells also are known.

[051] There are a number of ways in which expression vectors may be introduced into cells. In certain embodiments of the invention, the expression construct comprises a virus or engineered construct derived from a viral genome. The ability of certain viruses to enter cells via receptor-mediated endocytosis, to integrate into host cell genome, and express viral genes stably and efficiently have made them attractive candidates for the transfer of foreign genes into mammalian cells (Ridgeway, 1988; Nicolas and Rubinstein, In: Vectors: A survey of molecular cloning vectors and their uses, Rodriguez and Denhardt, eds., Stoneham: Butterworth, pp. 494-513, 1988.; Baichwal and Sugden, Baichwal, In: Gene Transfer, Kucherlapati R, ed., New York, Plenum Press, pp. 117-148, 1986. 1986; Temin, In: Gene Transfer, Kucherlapati, R. ed., New York, Plenum Press, pp. 149-188, 1986). Preferred gene therapy vectors are generally viral vectors.

#### AKT1 inhibitors

[052] The Ad36 composition can comprise any AKT1 inhibitor, including 2-ATD; AKT-I-1 (8); 2,3-diphenylquinoxaline (9); regioisomers of 5,6-diphenylpyrazin-2(1H)-ones (pyrazinones) (9); or 8-[4-(1-Aminocyclobutyl)phenyl]-9-phenyl[1,2,4]triazolo[3,4-f]-1,6-naphth- yridin-3(2H)-one (US Patent 7,576,209). Preferably, the AKT1 inhibitor is 2-ATD.

#### Administering Ad36 Compositions and AKT1 Inhibitors

[053] A variety of routes of administration are possible including, but not necessarily limited to parenteral (e.g., intravenous, intraarterial, intramuscular, subcutaneous injection), oral (e.g., dietary), topical, inhalation (e.g., intrabronchial, intranasal or oral inhalation, intranasal drops), or rectal.

[054] The Adenovirus-36 E4orf1 protein or fragments thereof, or its derivatives, can be administered by introducing into the mammal a nucleic acid

sequence encoding the Adenovirus-36 E4orf1 protein, in a manner permitting expression of the Adenovirus-36 E4orf1 protein. In such method, the nucleic acid sequence can be introduced by a method selected from the group consisting of electroporation, DEAE Dextran transfection, calcium phosphate transfection, cationic liposome fusion, protoplast fusion, creation of an in vivo electric field, DNA-coated microprojectile bombardment, injection with recombinant replication-defective viruses, homologous recombination, in vivo gene therapy, ex vivo gene therapy, viral vectors, naked DNA transfer, and using a nanotechnology delivery system.

[055] Formulation of an Ad36 composition and AKT1 inhibitor to be administered will vary according to the route of administration selected (e.g., solution, emulsion, capsule) and the individual to be treated. An appropriate composition comprising the compound to be administered can be prepared in a physiologically acceptable vehicle or carrier. For solutions or emulsions, suitable carriers include, for example, aqueous or alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media. Parenteral vehicles can include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's or fixed oils. Intravenous vehicles can include various additives, preservatives, or fluid, nutrient or electrolyte replenishers (See, generally, Remington's Pharmaceutical Science, 16th Edition, Mack, Ed. 1980). For inhalation, the compound is solubilized and loaded into a suitable dispenser for administration (e.g., an atomizer, nebulizer or pressurized aerosol dispenser), or formulated as a respirable dry powder. The Ad36 composition and AKT1 inhibitor can be separately formulated or co-formulated.

[056] The Ad36 composition and AKT1 inhibitor can be administered in a single dose or multiple doses. Therapeutically effective amounts are administered. A therapeutically effective amount is an amount sufficient to produce the intended effect under the conditions of administration. For example, an amount of Ad36 composition that is sufficient to increase fat

oxidation, increase transport of fat out of the liver, to lower Glut2 abundance in the liver, to reduce G6Pase in the liver, to enhance adiponectin, and/or Glut4, to improve glycemic control and/or to improve liver function can be administered. An amount of AKT1 inhibitor that is sufficient to inhibit adipogenesis, reduce mRNA levels of PPAR $\gamma$  and/or adiponectin function can be administered. The appropriate dosages can be determined by a clinician of ordinary skill using methods known in the art, which take into consideration the individual's age, sensitivity to drugs, tolerance to drugs, severity of disease and overall well-being, as well as other factors. Suitable dosages can be from about 0.1-about 10.0 mg/kg body weight per treatment.

[057] The entire teachings of all documents cited herein are hereby incorporated herein by reference.

#### Ad36 E4orf1 Sequences

Ad-36 E4orf1 DNA sequence (SEQ ID NO. 1)

```
ATGGCTGAATCTCTGTATGCTTTCATAGATAGCCCTGGAGG
GATCGCTCCCGTCCAGGAAGGGGCTAGCAATAGATATATCTTCTTTT
CC
CCGAATCTTTCCACATTCTCCGCATGGGGTGATATTGCTTCACCTCAG
A
GTGAGCGTGCTGGTTCCTACTGGATATCAGGGCAGATTTATGGCCTTG
AA
TGACTACCATGCCAGGGGCATACTAACCCAGTCCGATGTGATATTTGC
CG
GGAGAAGACATGATCTCTCTGTGCTGCTCTTTAACCACACGGACCGAT
TT
TTGTATGTCGCGAGGGCCACCCAGTGGGAACCCTGCTGCTGGAGAGA
GT GATTTTTTCCTTCAGTGAGAATAGCCACCCTGGTTTAG
```



Ad-36 E4orf1 Protein translation (SEQ ID NO. 2)

MAESLYAFIDSPGGIAPVQEGASNRYIFFCPESFHIPPHGV  
ILLHLRVSVLVPTGYQGGRFMALNDYHARGILTQSDVIFAGRRHDLSVLLF  
NHTDRFLYVREGHPVGTLLLERVIFPSVRIATLV

### EXEMPLIFICATION

[058] The results of the studies disclosed herein revealed that there is a link between Ad36 infection in humans and better glycemic control. The results also demonstrate that the Ad36 E4orf1 protein when combined with an AKT1 inhibitor improves glucose disposal, without increasing adipogenesis. Thus, these studies disclosed herein show that Ad36, Ad36 E4orf1, and functional variants combined with an AKT1 inhibitor can be used to treat or prevent hyperglycemia, insulin resistance, prediabetes, diabetes (type 1 or 2), and improve glycemic control without increasing adipogenesis.

[059] The interaction of Ad36 with AKT was investigated. AKT1, AKT2 and AKT3 are isoforms of this enzyme. Activation of AKT1 lead to an up-regulation of PPAR $\gamma$  and consequential adipogenesis, whereas, the activation of AKT2 lead to increased glucose uptake. AKT3 is primarily expressed in the brain.

[060] Ad36 infection up-regulated the activation of AKT1 and AKT2 in mice (FIGS. 2 & 3). Chow-fed mice infected with Ad36 increased adiposity in response to infection and yet, improved their glycemic control. This is reflected in greater activation of AKT1 and AKT2 in Ad36 infected chow fed mice. On the other hand, high-fat fed mice were already fat and did not increase adiposity further in response to Ad36 infection. They did however, improve glycemic control in response to Ad36 infection. This is reflected in greater AKT2

activation (but no difference in AKT1 activation) in these mice compared to uninfected controls. It was also discovered that Ad36 significantly increased the activation of AKT1 & AKT2 in differentiating preadipocytes (3T3-L1 cells), and increased AKT2 activation in differentiated 3T3-L1 adipocytes (FIGS. 4 & 5). 3T3-L1 cells were used as a model to study AKT enzymes further as described herein. Moreover, by selectively knocking down AKT1 or AKT2 using siRNA, it was shown that AKT2, but not AKT1, is required for Ad36 to enhance cellular glucose uptake (FIG 6).

### **Example 1**

#### **Ad36 activates AKT2 in high-fat (HF)-fed mice**

[061] Proteins were isolated from adipose tissue of HF-fed mice killed 20 weeks after infection with adenoviruses Ad36 or Ad2 (a negative control virus) or mock infection (n=3 mice/group). AKT2 protein was isolated with isoform-specific AKT antibodies by immunoprecipitation. The levels of total and phosphorylated AKT2 were determined by western blotting (FIG. 2A). Densitometry analysis was used to quantitate protein abundance and compared to Mean  $\pm$  SE. Ad36 infected mice, but not Ad2 infected group, had greater AKT2 activation (as indicated by greater phosphorylation) compared with mock (\*p<0.05) (FIG. 2B).

### **Example 2:**

#### **Ad36 activates AKT1 and AKT2 in Chow Fed Mice**

[062] Proteins were isolated from adipose tissue of chow-fed mice killed 12 weeks after infection with Ad36 or Ad2 or mock infection (n=3 mice/group). AKT1 and AKT2 proteins were isolated with isoform-specific AKT

antibodies by immunoprecipitation. The levels of total and phosphorylated AKT1 and AKT2 were determined by western blotting (FIG. 3A). Densitometry analysis was used to quantitate protein abundance and compare Mean  $\pm$  SE. Ad36 infected mice, but not Ad2 infected mice, had greater AKT1 and AKT2 activation (as indicated by greater phosphorylation) compared with mock (\* $p < 0.05$  or better) (FIG. 3B and 3C).

### **Example 3:**

#### **Ad36 activates AKT1 and AKT2 in 3T3L1 cells during differentiation**

[063] 3T3L1 preadipocytes were Ad36 or mock infected (n=3/group). 3T3L1 cells were induced to differentiate into adipocytes. Proteins were harvested 24, 48 and 72 hours after infection. AKT1 and AKT2 proteins were isolated with isoform-specific AKT antibodies by immunoprecipitation. The levels of total and phosphorylated AKT1 and AKT2 were determined by western blotting (FIG. 4A). Densitometry analysis was used to quantitate protein abundance and compare Mean  $\pm$  SE. Ad36 significantly induced increase in AKT1 and AKT2 activation compared with mock (\* $p < 0.05$  or better) (FIGS. 4B and 4C). The effect of Ad36 on AKT was similar to or better than that of insulin.

### **Example 4:**

#### **Ad36 activates AKT2 in 3T3L1 in adipocytes**

[064] Differentiated 3T3L1 adipocytes were Ad36 or mock infected (n=3/group). Proteins were harvested 24 hours post infection. AKT2 protein was isolated with isoform-specific AKT antibodies by immunoprecipitation. The levels of total and phosphorylated AKT2 were determined by western blotting

(FIG. 5A). Densitometry analysis was used to quantitate protein abundance and compare Mean  $\pm$  SE. Ad36 significantly increased AKT2 activation compared with mock (\* $p < 0.05$ ) (FIG. 5B).

#### **Example 5:**

##### **Glucose uptake after AKT knock down with siRNA**

[065] 2-deoxy glucose (2DG) uptake was determined under basal and insulin stimulated conditions 3 days post transfection, in 3T3-L1 preadipocytes. NT: cells transfected with non-targeting siRNA. Akt1 and Akt2: cells transfected with Akt1 and Akt2 siRNA. NT+Ad36: cells transfected with non-targeting siRNA and infected with Ad36. Akt1+36 and Akt2+36: cells transfected with Akt1 and Akt2 siRNA separately and infected with Ad36. Nt-Ins: cells transfected with non-targeting siRNA+ insulin. Akt1+Ins and Akt2+Ins: cells transfected with Akt1 and Akt2 siRNA + insulin. As expected, Ad36 significantly increased glucose uptake. The results show that knockdown of AKT2, but not of AKT1, decreased Ad36 induced glucose uptake (\* $p < 0.05$ ) (FIG. 6).

#### **Example 6:**

##### **Chemical inhibition of AKT1 using 2-ATD in inducible E4orf1 stable cell line**

[066] 3T3-L1 cells that express Ad36 E4orf1 when exposed to doxycycline (10) were generated. Cells that carry an empty vector (pTRE) and do not express E4orf1 in response to doxycycline were used as controls. Confluent E4orf1 and pTRE cells were exposed to adipogenic media to induce differentiation. In addition the cells were treated with 0, 1 or 5  $\mu$ M of 2ATD—a specific inhibitor of AKT1 signalling. This media was refreshed every two days

for up to nine days. Adipogenic differentiation was verified by oil red O staining (FIGS. 7A-F).

#### **Example 7:**

##### **Chemical inhibition of AKT1 using 2-ATD in inducible E4orf1 stable cell line**

[067] Confluent E4orf1 and pTRE cells were exposed to adipogenic media to induce differentiation. In addition the cells were treated with 0 or 5  $\mu$ M of 2ATD—a specific inhibitor of AKT1 signalling. This media was refreshed every two days for up to nine days. Basal and insulin stimulated 2DG uptake was determined 24 hours post induction in the presence of 1000 ng/ml of doxycycline expression of PPAR $\gamma$  and adiponectin—markers of adipogenesis, by qRT-PCR. As expected, E4orf1 expression significantly increased the expression of PPAR $\gamma$  and adiponectin. 2-ATD treatment significantly reduced PPAR $\gamma$  expression in pTRE as well as E4orf1 expressing cells (FIG. 8A) and adiponectin expression in E4orf1 expressing cells (FIG. 8B).

#### **Example 8**

##### **Basal and Insulin stimulated glucose uptake in presence of 2-ATD**

[068] E4orf1 and pTRE inducible stable cells were exposed to adipogenic media to induce differentiation and treated with 0 or 5  $\mu$ M of 2-ATD. Basal and insulin stimulated 2DG was determined 24 hours after exposure to doxycycline (1000 ng/ml), in presence or absence of insulin (\* $p$ <0.05). E4orf1 expression increased glucose uptake compared to that in pTRE. Despite 2-ATD treatment, E4orf1 expressing cells continued to show significantly greater glucose uptake (FIG. 9).

**Example 9****ATD Inhibits PPAR $\gamma$  Protein Abundance**

[069] 3T3-L1 adipocytes were transfected with a null vector and exposed to 10 $\mu$ M TZD, or transfected with a plasmid expressing E4orf1 protein. Both groups were exposed to 0, 1 or 5  $\mu$ M ATD. ATD reduced PPAR $\gamma$  protein abundance. Increasing concentration of ATD significantly reduced glucose uptake in the presence of TZD, but not when transfected with E4orf1 (FIG. 10). The glucose uptake in adipocytes was PPAR $\gamma$ -dependent in the presence of TZD, but not when induced by E4orf1. Thus, by down-regulating AKT-1 signaling E4orf1 can be used to enhance glucose uptake by adipocytes, without further increasing lipid accumulation. These data show a way to harness the anti-diabetic potential of E4orf1 without its adipogenic effect.

**REFERENCES**

1. Lindsley CW. The Akt/PKB family of protein kinases: a review of small molecule inhibitors and progress towards target validation: a 2009 update. *Curr Top Med Chem* 2010; **10**: 458-477.
2. Cho H, Thorvaldsen JL, Chu Q, Feng F, Birnbaum MJ. Akt1/PKB $\alpha$  is required for normal growth but dispensable for maintenance of glucose homeostasis in mice. *J Biol Chem* 2001; **276**: 38349-38352.
3. Cho H, Mu J, Kim JK, Thorvaldsen JL, Chu Q, Crenshaw EB, 3rd, *et al.* Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB  $\beta$ ). *Science* 2001; **292**: 1728-1731.
4. Garofalo RS, Orena SJ, Rafidi K, Torchia AJ, Stock JL, Hildebrandt AL, *et al.* Severe diabetes, age-dependent loss of adipose tissue, and mild growth deficiency in mice lacking Akt2/PKB  $\beta$ . *J Clin Invest* 2003; **112**: 197-208.

5. Hill MM, Clark SF, Tucker DF, Birnbaum MJ, James DE, Macaulay SL. A role for protein kinase B $\beta$ /Akt2 in insulin-stimulated GLUT4 translocation in adipocytes. *Mol Cell Biol* 1999; **19**: 7771-7781.
6. Easton RM, Cho H, Roovers K, Shineman DW, Mizrahi M, Forman MS, *et al.* Role for Akt3/protein kinase B $\gamma$  in attainment of normal brain size. *Mol Cell Biol* 2005; **25**: 1869-1878.
7. Luo J, Manning BD, Cantley LC. Targeting the PI3K-Akt pathway in human cancer: rationale and promise. *Cancer Cell* 2003; **4**: 257-262.
8. Barnett SF, Defeo-Jones D, Fu S, Hancock PJ, Haskell KM, Jones RE, *et al.* Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors. *Biochem J* 2005; **385**: 399-408.
9. Lindsley CW, Zhao Z, Leister WH, Robinson RG, Barnett SF, Defeo-Jones D, *et al.* Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors. *Bioorg Med Chem Lett* 2005; **15**: 761-764.

## CLAIMS

1. A method of improving glycemic control in an individual, comprising administering to an individual in need thereof a therapeutically effective amount of an Ad36 composition and an AKT1 inhibitor, wherein glycemic control is improved without substantial increase in adipogenesis.
2. A method of improving glycemic control in an individual, comprising administering to an individual in need thereof a therapeutically effective amount of an Ad36 composition and an AKT1 inhibitor, wherein insulin sensitivity is increased without substantial increase in adipogenesis.
3. A method of treating or preventing the symptoms of diabetes in an individual, comprising administering to an individual in need thereof a therapeutically effective amount of an Ad36 composition and an AKT1 inhibitor, wherein the individual's symptoms improve without substantial increase in adipogenesis.
4. The method of any one of claims 1-3, wherein said Ad36 composition comprises an Adenovirus-36 E4orf1 protein or functional variant thereof.
5. The method of any one of claims 1-3, wherein said Ad36 composition comprises a nucleic acid encoding Adenovirus-36 E4orf1 or functional variant thereof.
6. The method of any one of claims 1-3, wherein said Ad36 composition comprises an analog of Adenovirus-36 E4orf1.
7. The method of any one of claims 1-3, wherein an Adenovirus-36 E4orf1 protein is administered and the amino acid sequence of the Adenovirus-36 E4orf1 protein is SEQ ID NO:2 or functional variant thereof.
8. The method of any one of claims 1-3, wherein a nucleic acid encoding Adenovirus-36 E4orf1 protein is administered by introducing into the mammal a



nucleic acid sequence encoding the Adenovirus-36 E4orf1 protein, in a manner permitting expression of the Adenovirus-36 E4orf1 protein.


9. The method of claim 8, wherein the nucleic acid sequence is introduced by a method selected from the group consisting of electroporation, DEAE Dextran transfection, calcium phosphate transfection, cationic liposome fusion, proptoplast fusion, creation of an in vivo electric field, DNA-coated microprojectile bombardment, injection with recombinant replication-defective viruses, homologous recombination, in vivo gene therapy, ex vivo gene therapy, viral vectors, and naked DNA transfer.

10. The method of any one of claims 1-3, wherein the Ad36 composition comprises a nucleic acid sequence comprising SEQ ID NO:1 or functional variant thereof.

11. The method of any one of the preceding claims, wherein said individual is a human.

12. The method of any one of the preceding claims, wherein said AKT1 inhibitor is 2-Aminothiadiaazole (2-ATD).

Normal insulin signaling, and that utilized by Ad36



1/10

FIG. 1

+

2/10





FIG. 2

+




FIG. 3

+

4/10




FIG. 4

+

5/10





FIG. 5

+

6/10




FIG. 6

+

+

7/10





FIG. 7

+



8/10

A. PPAR $\gamma$  expression



B: Adiponectin expression




FIG. 8

9/10

Glucose uptake




FIG. 9

10/10




FIG. 10

## INTERNATIONAL SEARCH REPORT

International application No  
PCT/US2013/022126

<b>A. CLASSIFICATION OF SUBJECT MATTER</b> INV. A61K38/16 A61K45/06 A61K48/00 A61K31/145 A61P3/10 ADD.								
According to International Patent Classification (IPC) or to both national classification and IPC								
<b>B. FIELDS SEARCHED</b> Minimum documentation searched (classification system followed by classification symbols) A61K A61P Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) EPO-Internal, EMBASE, BIOSIS, WPI Data								
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b> <table border="1"> <thead> <tr> <th>Category*</th> <th>Citation of document, with indication, where appropriate, of the relevant passages</th> <th>Relevant to claim No.</th> </tr> </thead> <tbody> <tr> <td>A</td> <td>           EMILY J. DHURANDHAR ET AL: "E4orf1: A Novel Ligand That Improves Glucose Disposal in Cell Culture", PLOS ONE, vol. 6, no. 8, 23 August 2011 (2011-08-23), page e23394, XP055064780, DOI: 10.1371/journal.pone.0023394 page 10 abstract            -----            -/--         </td> <td>1-12</td> </tr> </tbody> </table>			Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.	A	EMILY J. DHURANDHAR ET AL: "E4orf1: A Novel Ligand That Improves Glucose Disposal in Cell Culture", PLOS ONE, vol. 6, no. 8, 23 August 2011 (2011-08-23), page e23394, XP055064780, DOI: 10.1371/journal.pone.0023394 page 10 abstract ----- -/--	1-12
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.						
A	EMILY J. DHURANDHAR ET AL: "E4orf1: A Novel Ligand That Improves Glucose Disposal in Cell Culture", PLOS ONE, vol. 6, no. 8, 23 August 2011 (2011-08-23), page e23394, XP055064780, DOI: 10.1371/journal.pone.0023394 page 10 abstract ----- -/--	1-12						
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.								
<p>* Special categories of cited documents :</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier application or patent but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"&amp;" document member of the same patent family</p>								
Date of the actual completion of the international search		Date of mailing of the international search report						
3 June 2013		10/06/2013						
Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016		Authorized officer Escobar Blasco, P						

## INTERNATIONAL SEARCH REPORT

International application No

PCT/US2013/022126

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>R. KRISHNAPURAM ET AL: "Template to improve glycemic control without reducing adiposity or dietary fat",  AJP: ENDOCRINOLOGY AND METABOLISM,  vol. 300, no. 5, 1 May 2011 (2011-05-01),  pages E779-E789, XP055064238,  ISSN: 0193-1849, DOI:  10.1152/ajpendo.00703.2010  page e785  page 787</p> <p style="text-align: center;">-----</p>	1-12
A	<p>O. DUBUISSON ET AL: "PPAR -Independent Increase in Glucose Uptake and Adiponectin Abundance in Fat Cells",  ENDOCRINOLOGY,  vol. 152, no. 10,  1 October 2011 (2011-10-01), pages  3648-3660, XP055064473,  ISSN: 0013-7227, DOI: 10.1210/en.2011-0225  abstract  page 3657, left-hand column</p> <p style="text-align: center;">-----</p>	1-12
A	<p>M. WAN ET AL: "Loss of Akt1 in Mice Increases Energy Expenditure and Protects against Diet-Induced Obesity",  MOLECULAR AND CELLULAR BIOLOGY,  vol. 32, no. 1,  1 January 2012 (2012-01-01), pages 96-106,  XP055064481,  ISSN: 0270-7306, DOI: 10.1128/MCB.05806-11  page 96</p> <p style="text-align: center;">-----</p>	1-12
A	<p>ZENG Q ET AL: "2-Aminothiadiaazole inhibitors of AKT1 as potential cancer therapeutics",  BIOORGANIC &amp; MEDICINAL CHEMISTRY LETTERS,  PERGAMON, ELSEVIER SCIENCE, GB,  vol. 20, no. 5, 1 March 2010 (2010-03-01),  pages 1652-1656, XP026911326,  ISSN: 0960-894X, DOI:  10.1016/J.BMCL.2010.01.046  [retrieved on 2010-02-17]  abstract</p> <p style="text-align: center;">-----</p>	1-12